tbuckley/cabot-search huggingface dataset:
Tomoelastography Distinguishes Noninvasively between Benign and Malignant Liver Lesions
Authors: Mehrgan Shahryari, Heiko Tzschätzsch, Jing Guo, Stephan R. Marticorena Garcia, Georg Böning, Uli Fehrenbach, Lisa Stencel, Patrick Asbach, Bernd Hamm, Joseph A. Käs, Jürgen Braun, Timm Denecke, Ingolf Sack
Journal: Cancer Research (2019)

Patients with increased liver stiffness have a higher risk of developing cancer, however, the role of fluid-solid tissue interactions and their contribution to liver tumor malignancy remains elusive. Tomoelastography is a novel imaging method for mapping quantitatively the solid-fluid tissue properties of soft tissues in vivo. It provides high resolution and thus has clear clinical applications. In this work we used tomoelastography in 77 participants, with a total of 141 focal liver lesions of different etiologies, to investigate the contributions of tissue stiffness and fluidity to the malignancy of liver tumors. Shear-wave speed (c) as surrogate for tissue stiffness and phase-angle (φ) of the complex shear modulus reflecting tissue fluidity were abnormally high in malignant tumors and allowed them to be distinguished from nontumorous liver tissue with high accuracy [c: AUC = 0.88 with 95% confidence interval (CI) = 0.83-0.94; φ: AUC = 0.95, 95% CI = 0.92-0.98]. Benign focal nodular hyperplasia and hepatocellular adenoma could be distinguished from malignant lesions on the basis of tumor stiffness (AUC = 0.85, 95% CI = 0.72-0.98; sensitivity = 94%, 95% CI = 89-100; and specificity = 85%, 95% CI = 62-100), tumor fluidity (AUC = 0.86, 95% CI = 0.77-0.96; sensitivity = 83%, 95% CI = 72-93; and specificity = 92%, 95% CI = 77-100) and liver stiffness (AUC = 0.84, 95% CI = 0.74-0.94; sensitivity = 72%, 95% CI = 59-83; and specificity = 88%, 95% CI = 69-100), but not on the basis of liver fluidity. Together, hepatic malignancies are characterized by stiff, yet fluid tissue properties, whereas surrounding nontumorous tissue is dominated by solid properties. Tomoelastography can inform noninvasively on the malignancy of suspicious liver lesions by differentiating between benign and malignant lesions with high sensitivity based on stiffness and with high specificity based on fluidity. SIGNIFICANCE: Solid-fluid tissue properties measured by tomoelastography can distinguish malignant from benign masses with high accuracy and provide quantitative noninvasive imaging biomarkers for liver tumors.
TCT-572 Clinical Outcomes of Critical Limb Ischemia Patients With Angiographic Dissection After Balloon Angioplasty for Infrapopliteal Artery Disease
Authors: Keisuke Hirano, Yoshiaki Ito, Tomoya Fukagawa, Motoharu Araki, Masahiro Yamawaki, Shinsuke Mori, Yasunari Sakamoto, Masakazu Tsutsumi, Yohsuke Honda, Kenji Makino, Shigemitsu Shirai, Masafumi Mizusawa, Norihiro Kobayashi
Journal: Journal of the American College of Cardiology (2019)
Abstract 14968: Role of Lysophosphatidylcholine 18:1 in Enterocytes of LDLR Null Mice on Western Diet
Authors: Pallavi Mukherjee, Greg Hough, Arnab Chattopadhyay, Victor Grijalva, Ellen I O’Connor, Xinying Yang, Alan Wagner, James M Ntambi, Mohamad Navab, Srinivasa T Reddy, Alan M Fogelman
Journal: Circulation (2017)

Introduction: We previously reported that adding 1 mg/gram of diet of lysophosphatidylcholine (LysoPC) 18:1 in chow-fed LDLR null mice resulted in dyslipidemia and systemic inflammation. The change...
Clonal Architecture of MDS Somatic Mutations Dynamically Changes during Azacitidine Therapy and Has Very Limited Potential to Predict Patient Outcome
Authors: Kamila Polgarova, Vojtech Kulvait, Karina Vargova, Lubomir Minarik, Nina Dusilkova, Zuzana Zemanova, Anna Jonasova, Tomas Stopka
Journal: Blood (2016)
John Richard Edmondson-Jones
Authors: Gwilym Edmondson-Jones
Journal: BMJ (2019)

John Richard Edmondson-Jones (“Jack”) entered RAF Cranwell and graduated in 1949, being presented with the Sword of Honour, the King’s Medal, and the John Anthony Chance Memorial Prize. Unfortunately on the night of 15 June 1950, he experienced a starboard engine failure on take-off in a DH Mosquito, sustained catastrophic injuries, and was admitted to Catterick military hospital. After three …
TCT-392 In-Hospital Outcomes of ST-Segment Elevation Myocardial Infarction Involving the Left Main Coronary Artery: Insights From the National Inpatient Sample
Authors: Mohamed Omer, Islam Elgendy, Ayman Elbadawi, Michael Megaly, Jonathan Enriquez, Hani Jneid, Yader Sandoval, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2019)
A Quarter of Participants With Advanced Neoplasia Have Discordant Results From 2-Sample Fecal Immunochemical Tests for Colorectal Cancer Screening
Authors: Els Wieten, Clasine M. de Klerk, Iris Lansdorp-Vogelaar, Patrick M. Bossuyt, Evelien Dekker, Manon C.W. Spaander
Journal: Clinical Gastroenterology and Hepatology (2019)
DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas
Authors: Marije E. Weidema, Ellen van de Geer, Christian Koelsche, Ingrid M.E. Desar, Patrick Kemmeren, Melissa H.S. Hillebrandt-Roeffen, Vincent K.Y. Ho, Winette T.A. van der Graaf, Yvonne M.H. Versleijen-Jonkers, Andreas von Deimling, Uta E. Flucke
Journal: Clinical Cancer Research (2019)

Abstract Purpose: DNA methylation profiling has previously uncovered biologically and clinically meaningful subgroups within many tumor types, but was not yet performed in angiosarcoma. Angiosarcoma is a rare sarcoma with very heterogeneous clinical presentations, which may be based on differences in biological background. In this exploratory study, DNA methylation profiling of 36 primary angiosarcoma samples from visceral, deep soft tissue, radiation-induced, and UV-induced localizations was performed. Experimental Design: Primary angiosarcoma formalin-fixed paraffin-embedded samples from visceral, soft tissue, radiation-induced, and UV-induced origin were collected from a nationwide search for angiosarcoma in the Netherlands. DNA was extracted for methylation profiling with the Illumina Infinium MethylationEPIC array. Quality control assessment and unsupervised hierarchical clustering were performed. Copy-number profiles were generated and analyzed for chromosomal stability. Clinical data were obtained from the Netherlands Cancer Registry. Results: DNA methylation profiling by unsupervised hierarchical clustering of 36 angiosarcoma samples (6 visceral, 5 soft tissue, 14 radiation-induced, 11 UV-induced) revealed two main clusters (A and B), which were divided into four subclusters. The clusters largely corresponded with clinical subtypes, showing enrichment of UV-induced cases in cluster A1 and radiation-induced cases in cluster A2. Visceral and soft tissue cases almost exclusively fell into cluster B. Cluster A showed significantly increased chromosomal instability and better overall survival (22 vs. 6 months, P = 0.046) compared with cluster B. Conclusions: In this novel methylation profiling study, we demonstrated for the first time four different angiosarcoma clusters. These clusters correlated with clinical subtype, overall survival, and chromosomal stability.
Prospective Study of Neuropathic Symptoms Preceding Clinically Diagnosed Diabetic Polyneuropathy: ADDITION-Denmark
Authors: Laura L. Määttä, Morten Charles, Daniel R. Witte, Lasse Bjerg, Marit E. Jørgensen, Troels S. Jensen, Signe T. Andersen
Journal: Diabetes Care (2019)

OBJECTIVE To evaluate whether diabetic polyneuropathy (DPN) follows the hypothesis for the course of nerve fiber damage reflected by symptoms progressing from pure small through mixed to large nerve fiber symptoms with or without symptoms of loss of function of small nerve fibers. RESEARCH DESIGN AND METHODS Repeated assessments of nerve fiber–specific symptoms were obtained in 518 participants of the ADDITION-Denmark study from the time of a screening-based diagnosis of type 2 diabetes using specific items of the Michigan Neuropathy Screening Instrument questionnaire. DPN was clinically assessed 13 years after inclusion. The course of symptoms reflecting dysfunction of specific nerve fibers was evaluated, and the association between symptoms and DPN was estimated using logistic regression models. RESULTS An overall stable, yet heterogeneous course of symptoms was seen. According to the hypothesis of symptom progression, 205 (40%) participants remained free of symptoms and 56 (11%) had stable, 114 (23%) progressing, and 132 (26%) improving symptoms. Cross-sectional estimates showed a higher risk of DPN (odds ratios between 2.1 and 4.1) for participants with mixed or large nerve fiber symptoms with or without symptoms of loss of function of small nerve fibers compared with participants without symptoms. CONCLUSIONS There was no evidence for a progressive development of nerve fiber damage in DPN reflected by symptoms going from pure small through mixed to large nerve fiber symptoms with or without symptoms of loss of function of small nerve fibers. Yet overall, neuropathic symptoms were prospectively associated with a higher risk of DPN.
Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in US Clinical Practice, with a Focus on Tyrosine Kinase Inhibitor Therapy Discontinuation
Authors: Ellen K Ritchie, Dominick Latremouille-Viau, Annie Guerin, Irina Pivneva, Karen Habucky, Briana Ndife, George J Joseph, Ehab Atallah
Journal: Blood (2017)
Crigler‐Najjar Syndrome Type 1: Pathophysiology, Natural History, and Therapeutic Frontier
Authors: Kevin A. Strauss, Charles E. Ahlfors, Kyle Soltys, George V. Mazareigos, Millie Young, Lauren E. Bowser, Michael D. Fox, James E. Squires, Patrick McKiernan, Karlla W. Brigatti, Erik G. Puffenberger, Vincent J. Carson, Hendrik J. Vreman
Journal: Hepatology (2019)

We describe the pathophysiology, treatment, and outcome of Crigler-Najjar type 1 syndrome (CN1) in 28 UGT1A1 c.222C>A homozygotes followed for 520 aggregate patient-years.Unbound ("free") bilirubin (Bf ) was measured in patient sera to characterize the binding of unconjugated bilirubin (BT ) to albumin (A) and validate their molar concentration ratio (BT /A) as an index of neurological risk. Two custom phototherapy systems were constructed from affordable materials to provide high irradiance in the outpatient setting; light dose was titrated to keep BT /A at least 30% below intravascular BT binding capacity (i.e., BT /A = 1.0). Categorical clinical outcomes were ascertained by chart review, and a measure (Lf ) was used to quantify liver fibrosis. Unbound bilirubin had a nonlinear relationship to BT (R2 = 0.71) and BT /A (R2 = 0.76), and Bf as a percentage of BT correlated inversely to the bilirubin-albumin equilibrium association binding constant (R2 = 0.69), which varied 10-fold among individuals. In newborns with CN1, unconjugated bilirubin increased 4.3 ± 1.1 mg/dL per day. Four (14%) neonates developed kernicterus between days 14 and 45 postnatal days of life; peak BT ≥ 30 mg/dL and BT /A ≥ 1.0 mol:mol were equally predictive of perinatal brain injury (sensitivity 100%, specificity 93.3%, positive predictive value 88.0%), and starting phototherapy after age 13 days increased this risk 3.5-fold. Consistent phototherapy with 33-103 µW/cm2 •nm for 9.2 ± 1.1 hours/day kept BT and BT /A within safe limits throughout childhood, but BT increased 0.46 mg/dL per year to reach dangerous concentrations by 18 years of age. Liver transplantation (n = 17) normalized BT and eliminated phototherapy dependence. Liver explants showed fibrosis ranging from mild to severe.Seven decades after its discovery, CN1 remains a morbid and potentially fatal disorder.
Letter to the Editor: Fair Comparisons in the Arena of Risk Scores
Authors: Junfeng Wang, Ronald B. Geskus, Mariska M.G. Leeflang, Cyriel Y. Ponsioen
Journal: Hepatology (2019)

Supported by the Wellcome Trust (grant number 106680/Z/14/Z). Potential conflict of interest: Dr. Ponsioen consults for, is on the speakers’ bureau for, and received grants from Takeda. He consults for Pliant and Shire and is on the speakers’ bureaus for Tillotts and AbbVie. To the Editor: We congratulate Goode and colleagues on their work.1 We are happy to see several research groups are working on this topic, underscoring the importance of the need for predicting outcomes of primary sclerosing cholangitis (PSC). The authors mention the Amsterdam‐Oxford PSC score, which contains similar variables and evaluates almost the same outcomes, and state that it has a moderate C statistic of 0.68 and suggest the UK‐PSC score is superior due to its C statistic of 0.80. However, a C statistic is not an inherent feature of a model: it also depends on the features of the cohort, e.g., censoring distribution, correlation between predictors and outcome, even correlation between predictors; these can all influence the best possible C statistic that can be achieved. Therefore, a fair way to compare two models predicting the same outcome is a direct comparison in the same external validation data set. Unfortunately, the authors only compared the performance of the UK‐PSC score with the Mayo score and aspartate aminotransferase‐to‐platelet ratio index and did not assess the Amsterdam‐Oxford PSC score as well. For an indirect comparison of the UK‐PSC score with the Amsterdam‐Oxford score, we would like to raise the following points: The short‐term 2‐year risk score (RSST) takes advantage of the fact that early events are easier to predict. If we apply the Amsterdam‐Oxford score only for the first 2 years, the C statistic is 0.76 (95% confidence interval [CI] 0.58‐0.94) in our external validation instead of 0.68. For the 10‐year risk of outcome score (RSLT), the longest prediction is 10 years (prediction at 2 years after diagnosis over the 8 following years), whereas the Amsterdam‐Oxford PSC score was evaluated with its prediction up to 30 years from time of diagnosis.2 If we evaluate the Amsterdam‐Oxford score only for events within 10 years, the C statistic is 0.71 (95% CI 0.62‐0.80) in our external validation. Furthermore, in Figure 3, calibration is not assessed by comparing predicted survival versus observed survival probability: it is actually between observed survival in the derivation cohort versus the validation cohort.1 From this figure, one cannot conclude that the calibration of RSLT is good. From a practical point of view, RSLT needs information both at T0 and T2; thus, prediction is only possible at T2. This is undesirable when counselling patients as to their prognosis after establishing a diagnosis of PSC. Instead of building a model at 2 years, an alternative method is to apply a so‐called dynamic prediction model, which can better reflect the dynamics of the disease progress than a baseline model.3
TCT-193 Sustained Safety and Efficacy of Magmaris Bioabsorbable Scaffold: A 2-Year Follow-Up Analysis From Pooled Multicenter Italian Experience
Authors: Stefano Galli, Piero Montorsi, Sarah Troiano, Claudio Rapetto, Francesco Pisano, Gianfranco Aprigliano, Massimo Leoncini, Paolo Mario Ravagnani
Journal: Journal of the American College of Cardiology (2019)
A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer
Authors: M. Ikeda, T. Okusaka, Y. Ito, H. Ueno, C. Morizane, J. Furuse, H. Ishii, M. Kawashima, Y. Kagami, H. Ikeda
Journal: Journal of Clinical Oncology (2006)

14003 Background: S-1 is a novel oral fluoropyrimidine derivative, and a phase II trial of this agent has demonstrated promising results with a response rate of 37.5% and a median survival of 8.8 months with a mild toxicity profile for patients with metastatic pancreatic cancer. This study investigated the maximum tolerated dose of S-1 based on the frequency of dose-limiting toxicities (DLT) of S-1 with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Patients and Methods: Patients with locally advanced pancreatic cancer in whom adenocarcinoma had been confirmed histologically or cytologically were enrolled in this study. S-1 was administered orally in escalating doses from 50 mg/m 2 , which is reported to be equivalent to 200 mg/m 2 intravenous 5-fluorouracil, to 80 mg/m 2 bid in 10 mg/m 2 increments on the day of irradiation (Monday through Friday) during radiotherapy. Radiation therapy was delivered through four fields as a total dose of 50.4 Gy in 28 fractions over 5.5 weeks. DLT was defined as grade 4 hematological toxicity and grade 3 or 4 non-hematological toxicity during chemoradiotherapy. The maximum tolerated dose was defined when three or more patients in a cohort of six patients experienced DLT. Results: Twenty-one patients (50 mg/m 2 3 patients; 60 mg/m 2 5 patients; 70 mg/m 2 6 patients; 80 mg/m 2 7 patients) were enrolled in this trial between May 2004 and November 2005. At 70 mg/m 2 S-1, two of six patients demonstrated DLT involving grade 3 nausea and vomiting and grade 3 hemorrhagic gastritis, while all patients at dose levels other than 70 mg/m 2 did not demonstrate any sign of dose-limiting toxicity. Of all 21 patients enrolled, 4 (19.0%) showed a partial response. More than a 50% reduction in the serum level of carbohydrate antigen 19–9 was observed in 12 (75%) of 16 patients in whom the pretreatment level was 100 U/ml or greater. Conclusion: The recommended dose of S-1 with concurrent radiotherapy is 80 mg/m 2 . This regimen may offer an easy alternative to intravenous 5-fluorouracil, and may be a promising treatment for locally advanced pancreatic cancer. A multicenter phase II trial of this regimen in patients with locally advanced pancreatic cancer is now underway. No significant financial relationships to disclose.
TCT-445 Radial Versus Femoral Access for Percutaneous Coronary Interventions in Patients With Chronic Total Occlusion
Authors: Giuseppe Ferrante, Yves Louvard, Kentaro Hayashida, Hakim Benamer, Thomas Hovasse, Thierry Unterseeh, Philippe Garot, Thierry Lefèvre
Journal: Journal of the American College of Cardiology (2012)
TCT-764 Comparison of 3rd Generation Self-Expanding and Balloon-Expandable Devices in Valve in Valve Treatment of Failing Aortic Valve Bioprostheses
Authors: Felix Woitek, Georg Stachel, Lisa Crusius, Stephan Haussig, David Holzhey, Holger Thiele, Mohamed Abdel-Wahab, Norman Mangner, Axel Linke
Journal: Journal of the American College of Cardiology (2019)
TCT-181 5-Year Outcomes of Patients Undergoing Everolimus-Eluting Bioresorbable Scaffold Implantation During Daily Clinical Routine: Final Results From the ISAR-Absorb Registry
Authors: Jens Wiebe, Petra Hoppmann, Tobias Rheude, Himanshu Rai, Roisin Colleran, Felix Voll, Salvatore Cassese, Michael Joner, Karl-Ludwig Laugwitz, Adnan Kastrati, Robert Byrne
Journal: Journal of the American College of Cardiology (2019)
TCT-101 Percutaneous Coronary Intervention of Aorto-Ostial Coronary Chronic Total Occlusion: Results and Technical Implications From a Multicenter Registry
Authors: Soledad Ojeda, Manuel Pan, Aurora Luque, Adrián Lostalo, Barbara Bellini, Iosif Xenogiannis, Francisco Hidalgo, Matteo Montorfano, Miguel Romero, Javier Suarez De Lezo, Mauro Carlino, Emmanouil Brilakis, Alessio La Manna, Lorenzo Azzalini
Journal: Journal of the American College of Cardiology (2019)
Plastic stents for refractory pancreatic duct strictures in chronic pancreatitis: the more the merrier
Authors: Vinay Chandrasekhara
Journal: Endoscopy (2019)

Pancreatic duct strictures due to chronic pancreatitis are often the most difficult for endoscopists to successfully remediate. There are multiple reasons for the suboptimal success rates for endoscopic therapy in this patient population, but one plausible explanation is that treating providers do not place large enough diameter stents for a prolonged duration.
TCT-649 Long-Term Prognosis of Elderly Patients With Additional High Bleeding Risk Factors: A Pooled Analysis From 4 Post-Approval XIENCE Studies
Authors: Yuqi Liu, Rishi Chandiramani, Davide Cao, Bimmer Claessen, Ridhima Goel, Moritz Blum, Anastasios Roumeliotis, Karine Piard-Ruster, Marco Valgimigli, Roxana Mehran
Journal: Journal of the American College of Cardiology (2019)
TCT-426 TAVR Versus SAVR for Bicuspid Aortic Valve
Authors: John Lisko, Samuel Maidman, Norihiko Kamioka, Robert Guyton, Patrick Gleason, Lucia Alvarez, Isida Byku, Kendra Grubb, Nikoloz Shekiladze, Beka Bakhtadze, Matthew Brown, Annie Ho, Siddhant Parihar, Jaffar Khan, Chandan Devireddy, Toby Rogers, Vasilis Babaliaros
Journal: Journal of the American College of Cardiology (2019)
Abstract P076: Genetic Predisposition to Hemoglobin A1 <sub>c</sub> , Postpartum Weight Reduction, and Glycemic Changes: A Longitudinal Study in Women With Prior Gestational Diabetes
Authors: Liyuan Han, Huikun Liu, Tiange Wang, Donghui Duan, Junhong Leng, Nan Li, Weiqin Li, Dianjianyi Sun, Gang Hu, Lu Qi
Journal: Circulation (2018)

Introduction: Hemoglobin A 1c (HbA 1c ) is a common marker for glycemic control and a major risk factor for diabetes and cardiovascular disease. Hypothesis: We examined whether the genetic variation predisposing to HbA 1c affected glycemic changes in women with prior gestational diabetes mellitus (GDM) and whether such an effect was modified by changes in body adiposity, especially during and after pregnancy. Methods: This is a longitudinal study in Tianjin, China. We genotyped 10 genome-wide association study-identified HbA 1c single nucleotide polymorphisms and assessed weight at 1 to 5 years postpartum and changes in glycemic traits in 1156 women with prior GDM. The genetic risk score was calculated based on 10 HbA 1c -associated loci. Main Outcome Measures: The main outcome measure was postpartum glycemic changes. Results: The HbA 1c genetic risk score significantly interacted with postpartum weight reduction on changes in 2-h glucose and HbA 1c (P for interaction = 0.02 and 0.03; respectively) after multivariable adjustment. In women with postpartum weight reduction of ≥8kg/y, the genetic risk score was associated with decreased HbA 1c . The association between postpartum weight reduction and glycemic improvement was more significant among women with a lower genetic risk score. Conclusions: In a large cohort of Chinese women with a history of GDM, our data for the first time indicate that the genetic predisposition to HbA 1c may interact with postpartum weight reduction on long-term glycemic changes. Figure 1. Changes in glycemic traits according to weight reduction and HbA 1C genetic risk score tertiles.
Risks of Bariatric Surgery Among Patients With End-stage Renal Disease
Authors: John R. Montgomery, Seth A. Waits, Justin B. Dimick, Dana A. Telem
Journal: JAMA Surgery (2019)

Risks of Bariatric Surgery Among Patients With End-stage Renal Disease2][3] Despite this, policies directly addressing pretransplant weight management do not exist.While the association between bariatric surgery and longterm weight loss and comorbidity improvement among obese patients with ESRD is well established, surgery is underused in this population owing to perceptions of unacceptable increased perioperative risk. 4,5Perioperative risks of bariatric surgery among obese patients with ESRD are poorly characterized, with limited studies that may not detect rare events. 6In this context, we performed an analysis of perioperative safety of bariatric surgery in obese patients with ESRD using a national registry capturing greater than 95% of bariatric operations.Methods | Patients who underwent primary, laparoscopic sleeve gastrectomy or roux-en-Y gastric bypass between 2015 and 2017 Figure.Rates of Perioperative Complications Between Patients With End-stage Renal Disease (ESRD) and Normal Kidney FunctionUnadjusted
TCT-467 In-Hospital and Long-Term Outcomes Among Patients With Spontaneous Coronary Artery Dissection Presenting With Ventricular Tachycardia and/or Fibrillation
Authors: Christopher Cheung, Andrew Starovoytov, Ashkan Parsa, Jason Andrade, Andrew Krahn, Matthew Bennett, Jacqueline Saw
Journal: Journal of the American College of Cardiology (2019)